Valuation: SciSparc Ltd.

Market Cap 3.06M 2.68M 2.5M 2.29M 4.3M 294M 4.37M 29.63M 11.58M 145M 11.47M 11.22M 500M P/E 2024
-0.33x
P/E 2025 -0.12x
Enterprise Value -1.17M -1.03M -955K -877K -1.65M -113M -1.67M -11.34M -4.43M -55.38M -4.39M -4.3M -191M EV / Sales 2024
-551,308x
EV / Sales 2025 289,759x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
1 day-6.82%
1 week+6.60%
Current month-3.44%
1 month-12.91%
3 months-20.33%
6 months-41.36%
Current year-56.45%
1 week 4.6
Extreme 4.6
6.46
1 month 4.23
Extreme 4.23
6.46
Current year 2.98
Extreme 2.98
15.79
1 year 2.98
Extreme 2.98
80.1
3 years 2.98
Extreme 2.98
2,997.05
5 years 0.49
Extreme 0.4914
41,769.08
10 years 0.49
Extreme 0.4914
41,769.08
Manager TitleAgeSince
Chief Executive Officer 39 10/01/2022
Chief Executive Officer 62 21/08/2020
Chief Tech/Sci/R&D Officer 56 08/02/2016
Director TitleAgeSince
Chairman 62 10/01/2022
Chairman 79 21/09/2025
Director/Board Member 50 21/08/2020
Change 5-day change 1-year change 3-year change Capi.($)
-6.82%+6.60%-91.84%-99.79% 3.06M
-0.66%+0.44%+14.25%+77.26% 48.36B
+2.20%+1.41%+57.98%+112.68% 35.8B
+1.26%-0.57%-7.95%+33.74% 11.83B
-0.46%-3.06%+13.55%+78.32% 11.48B
-0.37%-0.37%+37.53%+140.99% 9.01B
+1.52%+0.39%+49.34%-7.78% 6.99B
-0.17%-2.92%+11.72%+32.23% 6.7B
-0.59%-1.95%+2.18%+179.57% 6.42B
-7.92%-13.61%-33.87%-3.07% 5.3B
Average -1.20%-1.23%+5.29%+54.42% 14.19B
Weighted average by Cap. +0.12%-0.45%+24.12%+82.01%

Financials

2024 2025
Net sales 1.31 1.15 1.07 0.98 1.84 125.77 1.87 12.67 4.95 61.83 4.9 4.8 213.79 0.86 0.75 0.7 0.64 1.21 82.43 1.22 8.3 3.24 40.53 3.21 3.14 140.12
Net income -6.28M -5.52M -5.13M -4.71M -8.85M -605M -8.99M -60.95M -23.81M -298M -23.59M -23.08M -1.03B -12.18M -10.7M -9.95M -9.13M -17.15M -1.17B -17.42M -118M -46.15M -577M -45.72M -44.73M -1.99B
Net Debt -2.01M -1.77M -1.64M -1.51M -2.83M -194M -2.88M -19.51M -7.62M -95.21M -7.55M -7.39M -329M -4.22M -3.71M -3.45M -3.17M -5.95M -407M -6.04M -40.98M -16.01M -200M -15.86M -15.52M -692M
Logo SciSparc Ltd.
Scisparc Ltd, formerly Therapix Biosciences Ltd, is an Israel-based pharmaceutical company committed to creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The Company is engaged in drug development programs based on repurposing cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA) and pain; THX-130 for the treatment of mild cognitive impairment (MCI) and traumatic brain injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
Employees
3
Date Price Change Volume
24/07/26 $5.330 -6.82% 11,703
23/07/26 $5.720 +18.18% 83,783
22/07/26 $4.840 +1.89% 10,988
21/07/26 $4.750 +1.06% 10,980
20/07/26 $4.700 -6.00% 23,689

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SPRC Stock